» Articles » PMID: 36394153

PK/PD Model-informed Dose Selection for Oncology Phase I Expansion: Case Study Based on PF-06939999, a PRMT5 Inhibitor

Overview
Publisher Wiley
Specialty Pharmacology
Date 2022 Nov 17
PMID 36394153
Authors
Affiliations
Soon will be listed here.
Abstract

The optimal dose for targeted oncology therapeutics is often not the maximum tolerated dose. Pharmacokinetic/pharmacodynamic (PK/PD) modeling can be an effective tool to integrate clinical data to help identify the optimal dose. This case study shows the utility of population PK/PD modeling in selecting the recommended dose for expansion (RDE) for the first-in-patient (FIP) study of PF-06939999, a small-molecule inhibitor of protein arginine methyltransferase 5. In the dose escalation part of the FIP trial (NCT03854227), 28 patients with solid tumors were administered PF-06939999 at 0.5 mg, 4 mg, 6 mg, or 8 mg once daily (q.d.) or 0.5 mg, 1 mg, 2 mg, 4 mg, or 6 mg twice daily (b.i.d.). Tolerability, safety, PK, PD biomarkers (plasma symmetrical dimethyl-arginine [SDMA]), and antitumor response were assessed. Semimechanistic population PK/PD modeling analyses were performed to characterize the time-courses of plasma PF-06939999 concentrations, plasma SDMA, and platelet counts collected from 28 patients. Platelet counts were evaluated because thrombocytopenia was the treatment-related adverse event with clinical safety concern. The models adequately described the PK, SDMA, and platelet count profiles both at individual and population levels. Simulations suggested that among a range of dose levels, 6 mg q.d. would yield the optimal balance between achieving the PD target (i.e., 78% reduction in plasma SDMA) and staying below an acceptable probability of developing grade ≥3 thrombocytopenia. As a result, 6 mg q.d. was selected as the RDE. The model-informed drug development approach informed the rational dose selection for the early clinical development of PF-06939999.

Citing Articles

Targeting RNA splicing modulation: new perspectives for anticancer strategy?.

Lv X, Sun X, Gao Y, Song X, Hu X, Gong L J Exp Clin Cancer Res. 2025; 44(1):32.

PMID: 39885614 PMC: 11781073. DOI: 10.1186/s13046-025-03279-w.


Epigenetics-targeted drugs: current paradigms and future challenges.

Dai W, Qiao X, Fang Y, Guo R, Bai P, Liu S Signal Transduct Target Ther. 2024; 9(1):332.

PMID: 39592582 PMC: 11627502. DOI: 10.1038/s41392-024-02039-0.


Comprehensive biomarker and modeling approach to support dose finding for BI 836880, a VEGF/Ang-2 inhibitor.

Keller S, Kunz U, Schmid U, Beusmans J, Buchert M, He M J Transl Med. 2024; 22(1):934.

PMID: 39402675 PMC: 11476076. DOI: 10.1186/s12967-024-05612-x.


Phase I/II study of the clinical activity and safety of GSK3326595 in patients with myeloid neoplasms.

Watts J, Minden M, Bachiashvili K, Brunner A, Abedin S, Crossman T Ther Adv Hematol. 2024; 15:20406207241275376.

PMID: 39290981 PMC: 11406655. DOI: 10.1177/20406207241275376.


Role of pharmacometrics and systems pharmacology in facilitating efficient dose optimization in oncology.

Jayachandran P, Desikan R, Krishnaswami S, Hennig S CPT Pharmacometrics Syst Pharmacol. 2023; 12(11):1569-1572.

PMID: 37849052 PMC: 10681474. DOI: 10.1002/psp4.13066.


References
1.
Marshall S, Burghaus R, Cosson V, Cheung S, Chenel M, DellaPasqua O . Good Practices in Model-Informed Drug Discovery and Development: Practice, Application, and Documentation. CPT Pharmacometrics Syst Pharmacol. 2016; 5(3):93-122. PMC: 4809625. DOI: 10.1002/psp4.12049. View

2.
Mittapalli R, Guo C, Drescher S, Yin D . Oncology dose optimization paradigms: knowledge gained and extrapolated from approved oncology therapeutics. Cancer Chemother Pharmacol. 2022; 90(3):207-216. DOI: 10.1007/s00280-022-04444-0. View

3.
Jensen-Pergakes K, Tatlock J, Maegley K, McAlpine I, McTigue M, Xie T . SAM-Competitive PRMT5 Inhibitor PF-06939999 Demonstrates Antitumor Activity in Splicing Dysregulated NSCLC with Decreased Liability of Drug Resistance. Mol Cancer Ther. 2021; 21(1):3-15. DOI: 10.1158/1535-7163.MCT-21-0620. View

4.
Lignet F, Becker A, Gimmi C, Rohdich F, El Bawab S . Using thrombocytopenia modeling to investigate the mechanisms underlying platelet depletion induced by pan-proteasome inhibitors. CPT Pharmacometrics Syst Pharmacol. 2021; 11(5):594-603. PMC: 9124357. DOI: 10.1002/psp4.12743. View

5.
Kummar S, Gutierrez M, Doroshow J, Murgo A . Drug development in oncology: classical cytotoxics and molecularly targeted agents. Br J Clin Pharmacol. 2006; 62(1):15-26. PMC: 1885070. DOI: 10.1111/j.1365-2125.2006.02713.x. View